Elusys wins $143M contract for new anthrax treatment

The Department of Health and Human Services has awarded Elusys Therapeutics a contract worth up to $143 million for the development of a new anthrax therapy dubbed Anthim. The contract, which could run for up to five years, starts out with a $16.8 million payment in the first year. Analysts note that Elusys' new anthrax therapy could compete with Human Genome Sciences' raxibacumab. The FDA recently declined to approve HGS' anthrax treatment, noting some outstanding questions the agency has about raxibacumab's effectiveness compared with already marketed drugs. 

- read the report from the Washington Business Journal

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.